Literature DB >> 16148733

Management strategies for patients with amyotrophic lateral sclerosis from diagnosis through death.

Zachary Simmons1.   

Abstract

BACKGROUND: Amyotrophic lateral sclerosis (ALS) is a progressive neuromuscular disorder that is inevitably fatal. There are no effective treatments to stop or reverse the natural course of the disease. The role of the physician is to provide comfort and optimize quality of life. REVIEW
SUMMARY: Management of patients with ALS is a process extending over months to years. It begins with breaking the news of the diagnosis and extends through the terminal phase. Medication may extend lifespan by a small amount. However, most efforts are centered around symptom management. Areas of importance include respiration, nutrition, secretions, communication, pseudobulbar affect, therapy and exercise, spasticity and cramps, pain, depression and suicide, spirituality and religion, cognitive changes, the development of advance directives, and care at the end of life. Multidisciplinary ALS clinics provide much-needed support for patients with ALS and their caregivers.
CONCLUSION: Although physicians cannot cure ALS or even halt progression, there is much that can be done to manage the physical and emotional symptoms, thereby maintaining or enhancing quality of life.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16148733     DOI: 10.1097/01.nrl.0000178758.30374.34

Source DB:  PubMed          Journal:  Neurologist        ISSN: 1074-7931            Impact factor:   1.398


  22 in total

1.  ALS multidisciplinary clinic and survival. Results from a population-based study in Southern Italy.

Authors:  Stefano Zoccolella; Ettore Beghi; Guerrino Palagano; Angela Fraddosio; Vito Guerra; Vito Lepore; Isabella Laura Simone; Paolo Lamberti; Luigi Serlenga; Giancarlo Logroscino
Journal:  J Neurol       Date:  2007-04-13       Impact factor: 4.849

2.  End-of-life caregiving trajectories.

Authors:  Janice Penrod; Judith E Hupcey; Brenda L Baney; Susan J Loeb
Journal:  Clin Nurs Res       Date:  2011-02       Impact factor: 2.075

Review 3.  Symptom Management and End-of-Life Care in Amyotrophic Lateral Sclerosis.

Authors:  Carlayne E Jackson; April L McVey; Stacy Rudnicki; Mazen M Dimachkie; Richard J Barohn
Journal:  Neurol Clin       Date:  2015-11       Impact factor: 3.806

Review 4.  Plasma and cerebrospinal fluid-based protein biomarkers for motor neuron disease.

Authors:  Christi Kolarcik; Robert Bowser
Journal:  Mol Diagn Ther       Date:  2006       Impact factor: 4.074

5.  Pain in Amyotrophic Lateral Sclerosis: a psychological perspective.

Authors:  Francesco Pagnini; Christian Lunetta; Paolo Banfi; Gabriella Rossi; Federica Fossati; Anna Marconi; Gianluca Castelnuovo; Massimo Corbo; Enrico Molinari
Journal:  Neurol Sci       Date:  2011-12-20       Impact factor: 3.307

Review 6.  Depression and anxiety in individuals with amyotrophic lateral sclerosis: epidemiology and management.

Authors:  Anja Kurt; Femke Nijboer; Tamara Matuz; Andrea Kübler
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

Review 7.  Patient-Perceived Outcomes and Quality of Life in ALS.

Authors:  Zachary Simmons
Journal:  Neurotherapeutics       Date:  2015-04       Impact factor: 7.620

8.  Depression and quality of life in patients with amyotrophic lateral sclerosis.

Authors:  Dorothée Lulé; Sonja Häcker; Albert Ludolph; Niels Birbaumer; Andrea Kübler
Journal:  Dtsch Arztebl Int       Date:  2008-06-06       Impact factor: 5.594

9.  Symptom frequency, severity, and quality of life among persons with three disease trajectories: cancer, ALS, and CHF.

Authors:  Jiayun Xu; Marie T Nolan; Katherine Heinze; Gayane Yenokyan; Mark T Hughes; Julie Johnson; Joan Kub; Carrie Tudor; Daniel P Sulmasy; Lisa Soleymani Lehmann; Joseph J Gallo; Felicia Rockko; Mei Ching Lee
Journal:  Appl Nurs Res       Date:  2015-03-13       Impact factor: 2.257

10.  Patient-reported problematic symptoms in an ALS treatment trial.

Authors:  Divisha Raheja; Helen E Stephens; Erik Lehman; Susan Walsh; Chengwu Yang; Zachary Simmons
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2016-01-29       Impact factor: 4.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.